Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates.
The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Teofilo David Raad MBA |
Contact Details
Address: 36 Crosby Drive, Suite 100 Bedford, Massachusetts 01730 United States | |
| Phone | (781) 357-2333 |
| Website | pulmatrix.com |
Stock Details
| Ticker Symbol | PULM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574235 |
| CUSIP Number | 74584P301 |
| ISIN Number | US74584P3010 |
| Employer ID | 46-1821392 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Teofilo David Raad MBA | President, Chief Executive Officer and Director |
| Peter Ludlum CMA, MBA | Interim Chief Financial Officer and Principal Accounting and Financial Officer |
| Dr. Alexander M. Klibanov Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | 8-K | Current Report |
| May 30, 2024 | EFFECT | Notice of Effectiveness |
| May 29, 2024 | 8-K | Current Report |
| May 23, 2024 | UPLOAD | Filing |
| May 17, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 15, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 28, 2024 | 10-K | Annual Report |